To date, treatments with the objective to improve the quantity and quality of CD4+ T cells in COVID-19 have focused on addressing hyperactivation, anergy, or modulating specific cytokines, such as IL-1 and IL6 [43,71]. This evidence concerns the gene IL1B and COVID-19.